Vital Signs - Pharmacogenomics and Drugs: Now its Personal!

 


This issue of Vital Signs, released on November 23, 2009, provides a strategic overview of trends in pharmacogenomic testing and drug development. Additionally, a company spotlight is provided for Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative new therapies that treat and prevent infectious diseases and other disorders. Reimbursement and regulatory news from the FDA is also provided for the week of November 9, 2009.

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

Table of Contents

Vital Signs - Pharmacogenomics and Drugs: Now it’s Personal!Vital Signs: 23 November 2009This week's issue:




Related Research

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 24-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.